Bayer’s efforts to insure safety and restore Xofigo production
Malecare received more detail from Ms. Gissoo Decotis, Deputy Director of Oncology Advocacy Relations Bayer HealthCare, LLC. The following is about Bayer's efforts to insure safety and get Xofigo back into the market. "Following extensive [...]
Bayer HealthCare Announces the Resumption of the Production of Xofigo (Ra 223 dichloride)
Bayer HealthCare has announced that they have now resumed production of Xofigo (Ra 223 dichloride). Bayer has indicated that an initial lot of Xofigo has already been released so some patients will be able to [...]
Recipe for Fighting Prostate Cancer
Not all of us can or even want to grow mustaches. And even fewer of us want to bother our friends and neighbors about foot races or fundraising schemes. BUT>>> All of us eat food. [...]
Outcomes Analysis of Pooled Individual Data from Randomized Clinical Trials of Degarelix versus Luteinising Hormone-Releasing Hormone Agonists
Degarelex (Firmagon) (approved by the FDA in December of 2008) is a hormonal therapy drug used to treat advanced prostate cancer that has become metastatic and castrate resistant (mCRPC). Degarelix is a GnRH receptor that [...]
Good News from Bayer – The Xofigo Problem May Be Resolved & Bayer Hopes that the First Batch Will Be Delivered in November
Today, Bayer supplied Malecare with an update about the status of the Xofigo shortage. Bayer has told us that they have identified the cause of the problem and have implemented a system to resolve the [...]
We Need to Report Serious Adverse Events or Serious Drug Side Effects to the FDA – How You Can Make a Report
The Food and Drug Administration (FDA) is charged with protecting the general health and well being of Americans with medicines and certain treatment equipment. Sometimes these medications or treatment equipment fail, don't work as indicated [...]